drugset / Trial / NCT06082635
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 3
Active not recruiting
321 enrolled
Shenzhen TargetRx Co., Ltd.
Sun Yat-Sen University Cancer Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC
Timeline
- Start
- 2023-12-14
- Primary completion
- 2026-04-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Crizotinib | Small molecule | 250 mg | — |
| Subject | TGRX-326 | Unknown | 60 mg | — |